APA (7th ed.) Citation

Ament, M., Day, K., Stauffer, V. L., Skljarevski, V., Rettiganti, M., Pearlman, E., & Aurora, S. K. (2021). Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. Journal of headache and pain, 22(1), 100-2. https://doi.org/10.1186/s10194-021-01307-6

Chicago Style (17th ed.) Citation

Ament, Michael, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, and Sheena K. Aurora. "Correction to: Effect of Galcanezumab on Severity and Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine." Journal of Headache and Pain 22, no. 1 (2021): 100-2. https://doi.org/10.1186/s10194-021-01307-6.

MLA (9th ed.) Citation

Ament, Michael, et al. "Correction to: Effect of Galcanezumab on Severity and Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine." Journal of Headache and Pain, vol. 22, no. 1, 2021, pp. 100-2, https://doi.org/10.1186/s10194-021-01307-6.